CHF Solutions Sponsored AATS Session on Post-Cardiac Surgery, Highlighting Benefits of Using the Aquadex FlexFlow® System Fo...
June 13 2019 - 8:30AM
CHF Solutions (Nasdaq: CHFS), today announced highlights from the
sponsored session from the American Association for Thoracic
Surgery Annual Meeting moderated by Daniel Beckles, M.D., Ph.D. of
United Health Services Hospitals in Binghamton, N.Y. The full
session can be found on the company’s website at
www.chf-solutions.com.
The panel, titled “Personalized Medicine: Improving Clinical
Outcomes with Novel Fluid Management Strategies,” highlighted a
discussion on the use of the Aquadex FlexFlow system to help manage
risks associated with fluid overload in adult cardiac surgery
patients. Among the key reasons cited for using the device were the
ease of use for both doctors and other hospital staff, rapid
patient recovery, decrease in mortality, efficient utilization of
hospital resources, and the ability to personalize treatment based
on the individual patient’s need. The panel included Margarita
Camacho, M.D. (Newark Beth Israel), Mehdi Oloomi, M.D. (Mount Sinai
Health System), and Mark Small, M.S., PA-C (Medstar Franklin
Square), each of whom provided personal experience with the Aquadex
FlexFlow system in their institution.
“We continue to believe that utilizing ultrafiltration in
post-cardiovascular surgery provides medical personnel with an
important solution to treat fluid overload. The panel highlighted
that the Aquadex FlexFlow system provided a gentler methodology
that conformed to the physiology of each patient. We believe that
this personalized approach contributes both to the patient’s
recovery and the optimal utilization of hospital resources because
many patients spend less time in the intensive care unit and only
patients with urgent issues are receiving additional services,
rather than those patients who were simply experiencing fluid
overload,” said John Erb, chairman and CEO of CHF Solutions. “We
are grateful to Dr. Beckles for moderating this distinguished panel
and welcome medical professionals and investors alike to view it on
our website.”
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company
focused on developing, manufacturing and commercializing the
Aquadex FlexFlow system for aquapheresis therapy. Aquadex FlexFlow
system is a clinically proven therapy that provides a safe,
effective and predictable method of removing excess sodium and
fluid from patients suffering from fluid overload. The Aquadex
FlexFlow system is indicated for temporary (up to eight hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and extended (longer than 8 hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and require hospitalization. All treatments
must be administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies. The company's vision is to change the
lives of fluid overloaded patients through science, collaboration,
and innovative medical technology. CHF Solutions is a Delaware
corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, the effectiveness of the Aquadex FlexFlow system in
treating patients following cardiac surgery. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal DraytonChief Financial OfficerCHF Solutions,
Inc.952-345-4205ir@chf-solutions.com
-or-Bret ShapiroManaging PartnerCORE
IR516-222-2560brets@coreir.comwww.coreir.com
MEDIA
Jules AbrahamJQA Partners,
Inc.917-885-7378jabraham@jqapartners.com
Source: CHF Solutions, Inc.
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024